KAN-004

KAN-004 is a live biotherapeutic product (oral capsule, consortium of more than 100 microbial strains) from Kanvas Biosciences, with Centre hospitalier de l'Université de Montréal as partner. A consortium of more than 100 microbial strains, taken by mouth over 12 weeks, intended to restore the microbiome, gut barrier and immune balance in people who develop colitis from immune checkpoint inhibitor treatment. Its furthest stage is phase 1, for immune checkpoint inhibitor-induced colitis in people with solid tumours (supportive care). ClinicalTrials.gov registers it in one study linked below. Phase 1 recruiting at CHUM, announced 23 March 2026; registry status RECRUITING. Whether it works in people has not been established unless a trial below reports it.